The neurovascular unit (NVU) is comprised of vascular cells (pericytes, vascular smooth muscle cells (VSMCs), endothelial cells), glial cells (astrocytes, microglia, oligodendrocytes) and neurons [1] [2] [3] . Pericytes are centrally positioned in the NVU between endothelial cells, astrocytes and neurons (Fig. 1a) . They receive signals from their neighboring cells and generate functional responses that are essential for proper CNS functioning 2, [4] [5] [6] (Fig. 1b) .
r e v i e w Clearance. Pericytes can also act as perivascular tissue macrophages to clear tissue debris and foreign proteins injected systemically and/or locally in the CNS 2, 9, 10, 26, 27 and participate in clearance of Alzheimer's amyloid-β toxin, as shown in a murine Alzheimer's disease model 26 .
CBF. VSMCs control dilation and constriction of arterioles and small brain arteries 28, 29 . However, recent studies in cortical and cerebellar brain slices and retinal explants, as well as in vivo studies of cortical, retinal, olfactory bulb and ear microcirculation, have demonstrated that capillaries contribute to hemodynamic responses 19, [30] [31] [32] [33] [34] . It has been shown that pericytes regulate capillary tone and diameter 6, 18, 35 , as discussed in greater detail in the "Arachidonic acid pathway" section of this review. Some recent studies failed to find regulation of capillary blood flow by pericytes 36 , but the controversy has been attributed to a drift in pericyte definition, particularly renaming the mid-capillary pericytes into VSMCs 19 .
Neuroinflammation. Studies using transgenic pericyte-deficient mice have shown that pericytes control endothelial cell-mediated leukocyte adhesion and transmigration into the CNS 37 , and studies in wild-type mice demonstrate enhanced leukocyte trafficking in microvascular regions lacking pericyte coverage 38, 39 . In vitro studies have also suggested that pericytes influence neuroinflammation 40, 41 . Taken together, these findings suggest that immune activation of brain pericytes may contribute to communicating inflammatory signals in the NVU.
Stem cell activity. In vitro studies have suggested that cultured pericytes have multipotent stem cell potential 17, 42 . Moreover, primary murine pericytes isolated from brain following ischemic stroke exhibit multipotential stem cell activity and differentiate into neural and vascular lineage cells 42 .
Dysfunction. Pericyte degeneration leads to BBB breakdown causing brain accumulation of blood-derived neurotoxic molecules 10, [43] [44] [45] . Pericyte ischemic injury results in contractile rigor and obstruction of capillary blood flow 30, 46 . Pericyte-specific genetic defects lead to primary familial brain calcification, or Fahr's disease 47, 48 . Pericytes degenerate and likely play a role in cerebrovascular dysfunction in complex neurological diseases such as Alzheimer's disease 26, 49, 50 , amyotrophic lateral sclerosis (ALS) 51 and type 2 diabetes mellitusrelated microangiopathy and retinopathy [52] [53] [54] . Pericyte dysfunction has been also associated with HIV-related dementia 55 , epilepsy 56 , cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) 57 and brain cancer 58, 59 .
Pericyte-endothelial cell signal transduction PDGF-BB-PDGFRb pathway characterization. The platelet-derived growth factor (PDGF) family contains four ligands (A through D), which bind to two receptors (α and β) 59 . PDGF receptor tyrosine kinases (PDGFRs) form three active-conformation dimers: αα, ββ and αβ. The PDGF ligands differentially bind PDGFRs; specifically, where * denotes high affinity ligand-receptor interactions, PDGFR-αα's ligands are PDGF-AA*, PDGF-AB, PDGF-BB, and PDGF-CC*; PDGFR-αβ's ligands are PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD; and PDGFR-ββ's ligands are PDGF-BB* and PDGF-DD 59 . Here we will focus on PDGF-BB secreted by endothelial cells and PDGFRβ, a receptor on pericytes 5, 60, 61 .
Precise spatial and temporal regulation of PDGF-BB signaling is achieved via its retention motif, a region of positively charged amino acids at the C terminus. This motif binds to negatively charged heparin sulfate proteoglycans of the extracellular matrix, resulting in retention of PDGF-BB that generates a concentration gradient 5 , as shown by in vitro studies. PDGF-BB binds to PDGFRβ, causing non-covalent dimerization and autophosphorylation of the receptor on up to 13 cytoplasmic tyrosine residues, which activates PDGFRβ 62 (Fig. 2) . Once activated, distinct phosphorylated tyrosine residues of PDGFRβ are bound by specific Src homology 2 (SH2) domain-containing proteins, including phospholipase Cγ, Src family kinase, growth factor receptor-bound protein 2 (Grb2), phosphatidylinositol-3-OH kinase (PI3K), GTPase activating protein (GAP), SH2 tyrosine phosphatase (SHP2) and Stat5. These induce downstream signaling, which promotes pericyte survival, proliferation, migration and recruitment to the vessel wall 2, 62 .
RasGAP binding to phospho-PDGFRβ causes simultaneous binding of the Grb2 and son of sevenless homolog 1 (SOS1) complex to Ras that offsets the activation of Ras and reduces the downstream activity of the extracellular signal-regulated kinase-1 (ERK1) and ERK2, as Under physiological conditions (top row), pericytes regulate (1) BBB integrity, i.e., tight or adherens junctions and transcytosis across the BBB; (2) angiogenesis, i.e., microvascular remodeling, stability and architecture; (3) phagocytosis, i.e., clearance of toxic metabolites from the CNS; (4) CBF and capillary diameter; (5) neuroinflammation, i.e., leukocyte trafficking into the brain; and (6) multipotent stem cell activity. Pericyte dysfunction (bottom row) is characterized by (1) BBB breakdown causing leakage of neurotoxic blood-derived molecules into the brain (for example, fibrinogen, thrombin, plasminogen, erythrocyte-derived free iron and anti-brain antibodies); (2) aberrant angiogenesis; (3) impaired phagocytosis causing CNS accumulation of neurotoxins; (4) CBF dysfunction and ischemic capillary obstruction; (5) increased leukocyte trafficking promoting neuroinflammation; and (6) impaired stem cell-like ability to differentiate into neuronal and hematopoietic cells. Pericyte dysfunction is present in numerous neurological conditions and can contribute to disease pathogenesis.
npg r e v i e w Figure 2 PDGF-BB-PDGFRβ signaling in pericytes. PDGF-BB secreted by endothelial cells binds to PDGFRβ on pericytes, causing receptor dimerization, autophosphorylation and activation. Several SH2 domain-containing proteins bind to distinct phosphorylated (P) tyrosine residues, including Stat5, Src, SHP2, growth factor receptor-bound protein 2 (Grb2), GAP, PI3K and phospholipase Cγ (PLCγ). SH2 domain-containing proteins bound to PDGFRβ differentially activate downstream signaling pathways to regulate pericyte survival, migration, apoptosis, proliferation and differentiation, as well as leukocyte trafficking. Survival is promoted via PI3K-Akt activation of mammalian target of rapamycin (mTOR) and inhibition of caspase-9 and the SHP2-Grb2/SOS complex-mediated MAPK pathway involving sequential phosphorylation of MEK and ERK. Cell migration is promoted by the MAPK pathway's induction of cytoskeletal rearrangement. Specifically, Src-activated Raf, SHP2-activated Ras, and PI3K-Rho kinase (RhoK) phosphorylation of MEK synergistically activates the MAPK pathway whereas GAP inhibition of Ras decreases MAPK signaling. Extracellular advanced glycation end products (AGEs) induce intracellular ROS and FOXO1-mediated apoptosis. Additionally, hyperglycemia promotes PRKCD transcriptional expression of protein kinase C-δ (PKCδ), which activates p38α MAPK. p38α MAPK activates the specificity protein-1 (SP1) element of the PTPN6 promoter to express SH2 domaincontaining phosphatase-1 (SHP-1) which inhibits several receptor tyrosine kinases (RTK) (for example, PDGFRβ, insulin receptor, epidermal growth factor receptor (EGFR) and VEGFR2) and induces downstream production of ROS, causing mitochondrial cytochrome c release, resulting in apoptosis. Proliferation and differentiation are promoted by the PI3K pathway, specifically via PKC-TGF-β signaling, phosphatidylinositol-3,4,5-triphosphate (PIP3)-Akt transcriptional activation of NFκB and MAPK activation of cAMP response element-binding protein (CREB) to express interleukin-6 (IL-6). Peripheral leukocyte trafficking into the CNS is regulated in part by PDGFRβ-mediated proinflammatory responses, including transcriptional expression of immune response signaling genes (for example, cytokines and chemokines) and also Akt-induced activation of NFκB and transcriptional expression of activated leukocyte cell adhesion molecule (ALCAM). Red lines, inhibitory mechanisms; black lines, activator mechanisms; gray circle, cell nucleus.
shown in vitro 63 . Activation of Notch ligands and/or Notch receptors and activation of a Notch signal integrator transcription factor, CSL, can modulate PDGFRβ signaling independently of PDGF-BB, as shown using in vitro cultures and Notch3-deficient mice 64 (Fig. 2) .
PDGF-BB-PDGFRb pathway function. Developmental studies using
Pdgfb and Pdgfrb transgenic mouse models 60, 62 show that PDGF-BB-PDGFRβ signaling is important for endothelial-mesenchymal communication and CNS blood vessel development and stabilization 5 . Both Pdgfb null and Pdgfrb null mutations are embryonically lethal in mice and lead to development of CNS microvascular instability, endothelial hyperplasia, microaneurysms and blood vessel ruptures with microhemorrhages, whereas deletion of the single allele does not result in an apparent vascular phenotype in the developing CNS.
In contrast, during postnatal development, adulthood and aging, brain pericytes may fulfill a different regulatory role, as suggested by recent work in mouse models with partially disrupted PDGF-BB-PDGFRβ signaling as a result of either mutation in the PDGF-BB retention motif (Pdgfb ret/ret ) or deficient PDGFRβ signaling, both of which result in age-dependent BBB breakdown and accumulation of blood-derived neurotoxic proteins in the neuropil and brain interstitial fluid [8] [9] [10] . Deficient PDGFRβ signaling also leads to microvascular reductions, which in parallel with BBB breakdown may contribute to secondary neurodegeneration 10, 43 .
In animal models of diabetic retinopathy, hyperglycemia leads to diminished PDGFRβ signaling resulting in pericyte apoptosis 52 , whereas studies of tumor angiogenesis have shown that pericyte loss may lead to endothelial apoptosis 65 . PDGFRβ signal transduction in pericytes also mediates proinflammatory responses at the BBB by transcriptional regulation of several chemokines that promote endothelial expression of monocyte chemoattractant protein-1, nitric oxide (NO), interleukins IL-1, IL-6, IL-12, and tumor necrosis factor-α, resulting in transvascular trafficking of macrophages and leukocytes into the brain, as shown in pericyte-deficient Pdgfrb +/− mice 37 . Disrupted PDGF-BB-PDGFRβ signaling upregulates vascular endothelial growth factor (VEGF)-A, which accelerates vascular abnormalities, as shown in vivo in Pdgfb and Pdgfrb mutant mice 66 . Dysfunction in the PDGF-BB-PDGFRβ signaling pathway contributes to various CNS pathophysiologies, as discussed below. 26, 72, 73 . Moreover, plasma PDGF-BB levels are increased in people with Alzheimer's disease 74 , and soluble PDGFRβ levels, reflecting pericyte injury 75 , are increased in cerebrospinal fluid (CSF) of people with mild dementia, transgenic Alzheimer's disease mouse models, and pericyte-deficient mice 73 , suggesting dysfunction in PDGF-BB-PDGFRβ pathway as compared to control subjects or littermate control mice.
PDGF-BB-
In transgenic mice, deficient PDGFRβ signaling leads to pericyte loss, causing BBB disruption and microvascular reductions followed by neurodegenerative changes independently of amyloid-β (ref. 10) . However, studies in mice overexpressing amyloid-β precursor protein (APP) crossed with pericyte-deficient Pdgfrb +/− mice (APP Sw/0 ;Pdgfrb +/− mice) indicate that defective PDGF-BB-PDGFRβ signaling leads to faulty amyloid-β clearance from brain interstitial fluid by diminishing low-density lipoprotein receptor-related protein 1 (LRP1)-mediated amyloid-β clearance in pericytes 26 . Compared to control APP Sw/0 mice, which develop a moderate pericyte loss 26, 72 , APP Sw/0 ;Pdgfrb +/− mice have an earlier onset of cerebral amyloid angiopathy and amyloid-β load and increased amyloid-β 40 and amyloid-β 42 levels in the brain 26 . Accelerated pericyte degeneration in APP Sw/0 ;Pdgfrb +/− mice also leads to tau pathology and neuronal loss, which is not normally seen in APP Sw/0 mice 26 . These data suggest that a double vascular and amyloid-β hit is needed for the development of full-spectrum Alzheimer's disease-like pathology in mice. Whether the same double hit contributes to the pathogenesis of late-onset Alzheimer's disease in humans, which is characterized by pericyte degeneration 50, [69] [70] [71] [72] , is unclear.
Mutations in SORL1, SORCS1, SORCS2 and SORCS3 genes, encoding proteins containing vacuolar protein sorting-10 (Vps10) domains-namely, sorL1 (also known as sorLA) sorCS1, sorCS2 and sorCS3-are risk factors for sporadic Alzheimer's disease 76, 77 and diabetes 78 . Under normal conditions, sorL1 and sorCS1-3 interact with the retromer complex to facilitate intracellular trafficking, recycling, sequestration and metabolism of different proteins, including APP (ref. 79) . Single nucleotide polymorphisms in the genes encoding these proteins have been suggested to promote either aberrant APP clearance and/or processing 76 . PDGF-BB binds to sorL1, sorCS1 and sorCS3 (refs. 80,81) , which may influence its interaction with and/or downstream signaling from PDGFRβ that in turn might lead to pericyte dysfunction and/or degeneration, as seen in late-onset Alzheimer's disease 50, [69] [70] [71] 73 . In addition to PDGF-BB, sorL1 binds other LRP1 ligands similarly to LRP1 (ref. 81) , which may influence LRP1-mediated BBB clearance 82 . More studies are needed to evaluate the effects of interactions of PDGF-BB with sorL1 and sorCS1-3 on downstream PDGFRβ signaling in pericytes and whether these Vps10 proteins can provide a molecular link between Alzheimer's disease and diabetes pathogenesis.
Presenilin-1 (PSEN1) and PSEN2 mutations, the most frequent cause of autosomal-dominant Alzheimer's disease (ADAD) 83, 84 , both result in reduced PDGFRβ mRNA and protein levels, reduced PDGF-BB binding sites, and reduced PDGFRβ activation and autophosphorylation that consequentially suppress the downstream mitogen-activated protein kinase (MEK)-ERK and PI3K-Akt signaling pathways, as shown in PSEN1 and PSEN2 knockout cells 85 . These changes may lead to the pericyte degeneration and BBB disruption reported in post-mortem brains affected by ADAD 84 and PSEN1 transgenic mutants 86 . Elucidating the exact mechanism by which PSEN1 and PSEN2 mutations impair PDGF-BB-PDGFRβ signaling would inform how pericyte and microvascular dysfunction contributes to ADAD pathophysiology. Several dominantly inherited rare vasculotropic APP mutations in amyloid-β residues 21 to 23 (for example, Dutch, Flemish, Iowa and Arctic) primarily affect the cerebrovascular system, leading to BBB breakdown, cerebral amyloid angiopathy and hemorrhages with recurrent strokes, as recently reviewed 87 . Although APP mutations lead to degeneration of mural cells, whether deficient PDGF-BB-PDGFRβ signaling might contribute to loss of pericytes, rupture of blood vessels and/or BBB disruption is unknown. A possible mechanism illustrating how pericyte dysfunction and degeneration resulting from a deficient PDGF-BB-PDGFRβ pathway can contribute to dementia and Alzheimer's disease pathology in late-onset and early inherited familial cases is shown in Figure 3 . Figure 3 Deficient PDGF-BB-PDGFRβ signaling in pericytes may promote neuronal dysfunction and degeneration in Alzheimer's dementia. In the amyloid-β (Aβ)-independent pathway (pink box), deficient PDGF-BB-PDGFRβ signaling leads to pericyte dysfunction and/or degeneration, resulting in microvascular and CBF reductions and oligemia (brain hypoperfusion), and to BBB breakdown with accumulation of blood-derived toxic products in the brain. BBB breakdown leads to capillary edema contributing to capillary hypoperfusion and hypoxia. In the Aβ-dependent pathway (purple box), oligemia leads to increased Aβ production, whereas BBB breakdown and deficient PDGFRβ signaling can both lead to faulty Aβ clearance, which in turn promotes Aβ accumulation in the brain. Synergistic action of the Aβ-independent and Aβ-dependent pathways leads to accelerated tau hyperphosphorylation (pTau), formation of neurofibrillary tangles, synaptic dysfunction and loss and neuronal degeneration, which together promote behavioral deficits and dementia (blue box). r e v i e w PDGF-BB-PDGFRb signaling in ALS. Microvascular pathology is present in people with sporadic and familial ALS carrying superoxide dismutase 1 (SOD1) mutations 1, 51 . Pericyte degeneration in people with ALS coincides with BBB and blood-spinal cord barrier (BSCB) breakdown in motor-neuron-dense regions of the spinal cord and motor cortex 51 . Consistently, ALS model transgenic SOD1 mutant mice develop BSCB disruption, pericyte deficiency and erythrocyte extravasation before motor neuron dysfunction 43, 51, 88 . Moreover, preventing BSCB breakdown delays the onset of motor neuron disorder in SOD1 mutants 44 . Whether patients with the most frequent genetic cause of ALS, expanded hexanucleotide repeat of GGGGCC in a noncoding region of the C9Orf72 gene 89 , also develop pericyte degeneration and BBB breakdown and/or disrupted PDGF-BB-PDGFRβ signaling is unknown at present.
PDGF-BB-PDGFRb signaling in diabetes.
In type 2 diabetes mellitus and diabetic retinopathy, hyperglycemia influences the downstream PDGFRβ signal transduction cascade to induce pericyte apoptosis, as shown in vivo in rats and in vitro in retinal cultures [52] [53] [54] ( Fig. 2) . Hyperglycemia-induced apoptosis in vivo can be prevented by inhibition of the protein kinase C-δ-p38α-mitogen-activated protein kinase-14 (MAPK14)-SHP1 pathway 52 and advanced glycation end product (AGE)-induced apoptosis by PDGFRβ downstream activation of Akt and nuclear factor-κB (NFκB) 54 .
PDGF-BB-PDGFRb signaling in HIV-induced neurocognitive deficits.
HIV-1-positive individuals can develop HIV-associated neurocognitive disorders and HIV-associated dementia. Increased BBB permeability and pericyte loss, present in HIV-associated neurocognitive disorders and dementia, is thought to promote neurological impairments via increased transport of the HIV-1 viral neurotoxic protein Tat101 into the brain 55 . Interestingly, Tat101 increases PDGF-BB expression and PDGF-BB-PDGFRβ signaling, specifically via MAPK and NFκB activation, resulting in elevated pericyte migration and deficiency 55 .
PDGF-BB-PDGFRb signaling in brain cancer. The exact role of PDGFRβ signaling in pericytes in regulating growth and maturation of blood vessels in brain tumors remains still largely unexplored. Angiogenesis studies in the transgenic mouse model of pancreatic islet carcinogenesis (RIP1-Tag2) found that the broad-spectrum receptor tyrosine kinase inhibitor SU6668, which preferentially targets PDGFRβ, leads to regression of blood vessels by detaching pericytes from tumor vessels, which restricts tumor growth 90 . Similarly, SU6668 diminishes pericytes in xenograft tumors and restricts tumor growth 91 . Tumor-derived PDGFRβ + perivascular progenitor cells can differentiate into mature pericytes, eliciting vascular stabilization, maturation and survival 65 . Moreover, specific inhibition of PDGFRβ signaling eliminates PDGFRβ + perivascular progenitor cells and mature pericytes around tumor vessels, leading to endothelial cell apoptosis in transgenic RIP1-Tag2 mice with pancreatic islet tumors 65 .
A recent study has shown that PDGFRβ regulates cell proliferation and invasion of medulloblastomas via JAG2 (ref. 58) , suggesting that PDGFRβ could be a potential therapeutic target for medulloblastomas. It remains unclear, however, whether medulloblastoma cells have the potential to differentiate into pericytes, as shown for some other types of brain neoplastic cells that can generate pericytes to control blood vessel function during tumor growth 92, 93 .
TGF-b-TGFbR2 pathway characterization. Transforming growth factor-β (TGF-β) is expressed in a latent form by pericytes, endothelial cells, neurons and glia. Studies using in vitro primary cocultures of endothelial cells and pericytes indicate that TGF-β activation at the BBB requires pericyte-endothelial cell interaction 94 : specifically, formation of the gap junction connexin-43 hemichannels 95 . Activated TGF-β binds TGF-β receptor 2 (TGFβR2) on pericytes and endothelial cells 2, 5 . TGF-β-TGFβR2 signals downstream via activin receptorlike kinase 5 (Alk5) in both pericytes and endothelial cells or Alk1 only in endothelial cells, as shown in primary bovine retinal cultures 96 (Fig. 4) . In pericytes, Alk5-mothers against decapentaplegic homolog 2 (Smad2)/Smad3/Smad4 signaling inhibits proliferation and promotes differentiation 2, 5 (Fig. 4) . For example, mouse embryos with reduced TGFβR2-Alk5-Smad2/3 signaling exhibit enhanced pericyte proliferation 97 , and depleting TGF-β attenuates mural cell differentiation in murine embryonic mesenchymal cells and endothelial cell cocultures 98 . In endothelial cells, Alk5 and Alk1 induce opposing effects via distinct downstream signal transduction events 2, 5, 96 . Specifically, in vitro studies in murine embryonic endothelial cells reveal that TGF-β-TGFβR2 signals downstream via Alk5-Smad2/3/4 to induce PDGF-BB expression and activate the recombination signal sequence-binding protein-Jκ (RBP-Jκ) transcription factor to express N-cadherin and promote attachment, Alk1-Smad1/5/8 to promote proliferation, and the PI3K-Akt pathway to promote survival and transcriptionally induce proliferation 2,99,100 (Fig. 4) .
TGF-b-TGFbR2 pathway function. TGF-β-TGFβR2 signaling promotes cell differentiation, maturation, proliferation, migration and attachment of endothelial cells and pericytes, as shown by in vitro studies of endothelial cells and pericytes of mouse embryos or bovine retinas [96] [97] [98] and confirmed in vivo in murine models 99 . Studies using transgenic mice with disrupted TGF-β-TGFβR2 downstream signaling-as in, for example, Smad1, Smad2 and Smad4 knockout mice 100,101 -indicate that TGF-β-TGFβR2 downstream pathways regulate BBB formation, particularly the endothelial-to-mesenchymal transition during normal development and vascular stabilization, and that aberrant TGF-β-TGFβR2 signaling in this pathway leads to development of brain hemorrhages 99 .
Recent studies have shown that the forkhead transcription factor Foxf2 is specifically expressed in brain pericytes and that Foxf2 knockout embryos develop intracerebral hemorrhage, perivascular edema, thinning of the vascular basal lamina, an increase in luminal endothelial caveolae and BBB breakdown 97 .
TGF-b-TGFbR2 signaling in neonatal intraventricular hemorrhage. Intraventricular hemorrhage (IVH) is a major cause of mortality in premature infants, where it results from vascular instability due to pericyte deficiency 100 . TGF-β signaling induces N-cadherin expression to promote BBB integrity, whereas regional disruption in TGF-β signaling leads to the development of IVH, as shown in transgenic mice with endothelial cell-specific Smad4 knockout 100 . Mice are protected from IVH via perinatal glucocorticoid administration that increases TGF-β signaling, resulting in increased pericyte coverage 102 .
TGF-b-TGFbR2 signaling in cerebral cavernous malformation.
Cerebral cavernous malformation (CCM) is characterized by raspberry-like lesions of microvessels that exhibit pericyte deficiency and by enlarged endothelial cells with pinocytotic vesicles and poorly developed tight and adherens junctions, making the vessels prone to hemorrhaging 99, 103 . This phenotype is present in sporadic and familial CCM, including loss-of-function mutations in CCM1, CCM2 and CCM3 (ref. 104 ). An analogous vascular phenotype develops r e v i e w in mice with endothelial cell-specific inducible ablation of Ccm1 (iCcm1 ∆EC/EC ) (refs. 99, 103) and Ccm2 or Ccm3 mutations (ref. 99) . Disrupted TGF-β signaling at the BBB is reported in studies using iCcm1 ∆EC/EC mice, brain tissue from people with CCM, and cultured human brain vascular cells 99, 103 and contributes to CCM by inducing structural instability of capillaries. Human CCM3 also binds to paxillin, a scaffolding protein; and CCM3 and paxillin colocalize in mouse cerebral pericytes 105 .
TGF-b-TGFbR2 signaling in brain cancer. Several studies indicate that TGF-β signaling 93, 106, 107 and pericytes 93, 108 affect cancer growth and tumor-associated blood vessel function. For example, high TGF-β-Smad activity was found in aggressive, highly proliferative gliomas, and this activity confers poor prognosis in patients with glioma 106 . Transcriptomic analysis of primary cultured human gliomas and human glioma biopsies indicates that the TGF-β-Smad pathway promotes proliferation through the induction of PDGF-B in gliomas with an unmethylated PDGFB gene 106 .
More recent studies reveal that self-renewing tumorigenic glioma stem cells give rise to pericytes to support vessel formation and tumor growth 92, 93 . Glioma stem cells are recruited to endothelial cells by SDF-1, an α-chemokine that binds to G-protein-coupled CXCR4, and are induced to become pericytes predominantly by TGF-β (ref. 93) . TGF-β signaling has also been shown to regulate vascular phenotypes in gliomas and is sufficient to invoke many of the changes found in a gene signature associated with pathologically altered vessels in human glioblastoma grade IV (ref. 107).
TGF-b-TGFbR2 signaling in ischemic stroke. Multiple studies indicate that TGF-β-TGFβR2 signaling mediates angiogenic responses to brain injury due to ischemia or hypoxia 109 . In this context, TGF-β signaling stabilizes newly formed microvessels 110 .
Notch pathway characterization. Pericytes express Notch3 and endothelial cells express Notch1 and Notch4 receptors (Fig. 4) . Notch ligands such as delta-like ligand 4 (Dll4) and Jagged activate the receptor to induce cleavage of the Notch intracellular domain (NICD). NICD translocates to the nucleus and interacts with a Notch signal integrator transcription factor, the DNA-binding protein CSL complex (comprising C-promoter binding factor 1 (CBF-1)-RBP-Jκ, suppressor of hairless, and Lag-1), to induce transcription of downstream target genes, as shown in Notch3 knockout mice 111 . Ang1-Tie2 activates the PI3K-Akt pathway resulting in inhibition of glycogen synthase kinase 3β (GSK3β), an inhibitor of β-catenin; this leads to β-catenin nuclear translocation, activating TCF-LEF transcription factors that control expression of several proteins promoting BBB stability (for example, upregulation of claudin-5, Glut1, and ATP-binding cassette subfamily B member 1 (ABCB1), downregulation of plasmalemma vesicle associated protein (Plvap)-Meca23, and DLL4-mediated expression of VEGFR1 and inhibition of VEGFR2, VEGFR3 and neuropilin-1 (Nrp1); see box). Signaling through Notch1 or Notch4 receptors contributes to β-catenin-mediated BBB stability via Notch-regulated ankyrin repeat protein (Nrarp), which increases β-catenin nuclear signaling by inhibiting LEF1 degradation and decreases Notch signaling via NICD destabilization. Additionally, the Notch-NICD pathway stimulates PDGF-BB expression and RBP-Jκ-mediated expression of N-cadherin, contributing to BBB stability. As in pericytes, the TGF-β-TGFβR2 pathway in endothelium similarly activates (i) the Alk5-Smad2/3/4 complex to transcriptionally promote differentiation, inhibit proliferation and induce RBP-Jκ-mediated expression of N-cadherin, (ii) the Alk1-Smad1/5/8 complex to promote proliferation and (iii) the Alk1-PI3K-Akt pathway to promote survival and BBB stability. MFSD2A facilitates luminal-to-abluminal transport of docosahexaenoic acid (DHA), an essential omega-3 fatty acid, and controls formation of the BBB; its expression depends on the presence of pericytes. Red lines, inhibitory mechanisms; black lines, activator mechanisms; gray circle, cell nucleus.
npg r e v i e w
In endothelial cells, the Notch pathway is modulated by canonical Wnt signaling to influence vascular sprouting and remodeling 112 . The Wnt-β-catenin pathway in brain endothelium regulates differentiation of the brain vasculature, angiogenesis and BBB integrity, as shown by in vitro studies using primary mouse and rat brain microvascular endothelial cells and endothelial cells with conditional activation of β-catenin and by in vivo studies using Pdgfb-iCreERT2;Ctnnb1 lox/lox mice, Pdgfb-iCreER +/-;Nrarp -/-;Ctnnb1 lox(ex3)/lox(ex3) mice, TOP-Gal Wnt reporter mice and zebrafish 112, 113 .
Notch pathway: function. The Notch pathway regulates angiogenic sprouting and microvascular remodeling 111 . During sprouting angiogenesis, specialized endothelial tip cells lead the outgrowth of blood vessel sprouts toward gradients of VEGF-A (refs. 114,115). Studies using Dll4 +/− mice and mice with inducible endothelium-specific inactivation of Notch1 (Cdh5-CreER T2 ;R26R-Notch1 loxP/loxP mice), as well as Notch inhibition by γ-secretase inhibitors or activation with soluble Jagged-1 peptide, have demonstrated that Dll4-Notch1 signaling between endothelial cells in the angiogenic sprout restricts tip-cell formation in response to VEGF (ref. 116) . This model offers not only an explanation for the dose dependency and haploinsufficiency of the Dll4 gene 117, 118 , but also suggests that γ-secretase inhibitors and/or modulators of Dll4 or Notch signaling developed originally for Alzheimer's disease could also be used as pharmacological regulators of angiogenesis.
Notch signaling in neurological disorders. Several studies using transgenic models, human tissue and/or cultured brain vascular cells report that CCM is associated with disruptions in TGF-β and Notch signaling at the BBB 99, 103 . Much like disrupted TGF-β signaling, dysfunction in Notch signaling is associated with IVH, as observed in mouse knockouts of Rbpj (encoding the Notch-related RBP-Jκ transcription factor) 100 . In cultured glioblastoma stem cells, activating Notch1 signaling induces a vascularization switch and causes the glioblastoma stem cells to differentiate into pericyte-like cells (expressing PDGFRβ, NG2 and α-smooth muscle actin) with upregulated expression of angiogenic factors including cytokines, matrix metalloproteinase-9 (MMP-9) and adhesion molecules 92 .
VEGF-A-VEGFR2 pathway characterization and function. Pericytes (paracrine signaling) and endothelial cells (autocrine signaling) secrete VEGF-A, which activates the VEGF receptor-2 (VEGFR2) pathway to increase expression of antiapoptotic Bcl-2, survivin and X-linked inhibitor of apoptosis protein (XIAP), as shown by in vitro studies of human brain pericyte and endothelial cell cocultures 119 (Fig. 4) . For intracrine signaling, pericytes secrete vitronectin (in a PDGF-BB-PDGFRβ-dependent process) that activates integrin α V -NFκB signaling in endothelial cells to upregulate VEGF-A, which signals intracellularly via VEGFR2 to promote Bcl-w expression and cell survival, as shown by in vitro studies of human brain pericyte and endothelial cell cocultures 119 (Fig. 4) . VEGF-A-VEGFR2 signal transduction promotes cell survival, angiogenesis and vascular permeability 2, 119 .
VEGF-A-VEGFR2 signaling in ischemic brain injury and hypoxia.
In vivo studies in cats have shown that brain pericytes migrate away from capillaries rapidly following a hypoxic insult 120 , and the pericyteendothelial cell ratio in the brain is reduced 1 week after hypobaric hypoxia in rodents 121 . During hypoxia, VEGF levels are upregulated in pericytes within 24 h and upregulated in astrocytes after 4 d (ref. 121) . In in vitro endothelial and pericyte cocultures, inhibiting VEGF in chronic mild hypoxia (1% O 2 ) promotes angiopoietin-1 (Ang1)-mediated endothelial cell tight junction stabilization, whereas severe hypoxia (0.1% O 2 ) promotes apoptosis of endothelial cells 122 . Hypoxia activates hypoxia-inducible factor 1α, which translocates to the nucleus and binds hypoxia-response elements to induce transcription of target genes to promote angiogenesis (for example, by upregulating VEGF-A and MMPs), anaerobic metabolism, apoptosis, and cell survival and proliferation 123 .
VEGF-A-VEGFR2 signaling in brain cancer. Inhibition of VEGFinduced angiogenesis suppresses growth of human glioblastoma cells in vivo in mice 124 . Clinical trials with bevacizumab, a monoclonal antibody against VEGF-A, have shown it slows tumor growth in people with glioblastoma, but growth inevitably recurs 125 . Treatment with an anti-VEGF antibody was least effective in human subjects with glioblastoma exhibiting heightened CBF and angiogenesis 125 . VEGF-VEGFR2 signaling can also function as a negative regulator of receptor tyrosine kinases including PDGFRβ in pericytes 126 and mesenchymal-epithelial transition (MET) receptor in glioblastoma cells 127 . Pericytes in vitro are also reported to express VEGFR2; VEGF ablation in tumor cells disrupts PDGFRβ-VEGFR2 heterocomplex formation and downstream PDGFRβ signaling in pericytes and increases tumor vessel maturation 126 . MET is more abundantly expressed in glioblastoma tissue of patients who exhibit more resistance to bevacizumab 127 , suggesting that VEGFR2's association with receptor tyrosine kinases in pericytes may be important in promoting cancer cell maturation and/or tumor growth.
Ang-Tie2 pathway characterization and function. Ang1, secreted by pericytes, binds to the endothelial cell-specific Tie2 receptor tyrosine kinase and activates the downstream PI3K-Akt pathway in endothelial cells 5 . Angiopoietin-2 (Ang2), expressed by endothelial cells, was originally shown to inhibit Ang1-mediated phosphorylation of Tie2, as well as cellular responses during embryonic development 5 . Ang2 also has proangiogenic activities in adult tissues and cultured endothelial cells, independent of Ang1. For example, in the absence of Ang1, Ang2 binds endothelial Tie2 and activates the PI3K-Akt pathway in cultured endothelial cells, acting as a Tie2 agonist, but when Ang1 is present, Ang2 dose-dependently inhibits Ang1-induced Tie2 phosphorylation and endothelial cell survival, acting as a Tie2 antagonist 128 . Ang2 also binds to endothelial integrins (α v β 3 , α v β 5 , α 5 β 1 ) to induce phosphorylation of the integrin adaptor protein focal adhesion kinase (FAK) and activation of Rac1, which promotes endothelial cell migration and sprouting, as demonstrated in cultured Tie2-silenced endothelial cells and in vivo in human xenotransplanted endothelial cells in mice 129 .
Ang1 knockout mice exhibit pronounced angiogenic deficits in brain resulting in embryonic lethality, similarly to Tie2 knockout mice 130 . Studies using in vivo assays demonstrate attenuated vascular responses to histamine, bradykinin and VEGF in Ang2 −/− mice 131 . Recombinant Ang1 attenuates retinal vascular disruptions caused by pericyte loss 132 , whereas overexpressing Ang2 in the retina results in pericyte loss and aberrant retinal angiogenesis 133 . Furthermore, cytokine-induced intracellular calcium influx is impaired in Ang2-null endothelioma cells, consistent with reduced phospholipase activation in vivo 131 . Thus, the Ang-Tie2 system has a critical role in regulating angiogenesis and vascular permeability, but Ang1 and Ang2 exert diverse effects on endothelial cell functions depending on experimental conditions and models.
Ang-Tie2 signaling in neurological disorders. In the db/db transgenic mouse model of diabetes, ischemic stroke leads to enhanced BBB breakdown associated with increased expression of Ang2 and 134 . Ang2 is upregulated in tumors and thought to denote the onset of angiogenic sprouting 135 .
MFSD2A pathway characterization and function. The major facilitator superfamily domain-containing 2a (MFSD2A) is a sodium-dependent BBB transporter of long-chain fatty acids that is expressed in the brain exclusively in the endothelium, as indicated by studies in mice and humans 136, 137 . Studies in transgenic Mfsd2a null mice have shown that MFSD2A facilitates transport of docosahexaenoic acid (DHA), an essential omega-3 fatty acid, into the brain 136 . Its expression appears to depend on the presence of pericytes 137 , but the exact molecular pathway remains to be elucidated. MFSD2A exhibits dual functions at the BBB by regulating the formation and maintenance of BBB integrity 137 and delivery of essential fatty acids to the brain, as shown in vitro in endothelial cell cultures and in vivo in murine models 136, 137 .
MFSD2A signaling in microcephaly. Mfsd2a-deficient mice develop a reduced brain size, termed microcephaly 136 . Microcephaly syndrome in humans was recently shown to be caused by inactivating mutations in MFSD2A, and the syndrome's severity correlates with the degree of functional inactivation of the MFSD2A protein 138, 139 .
Ephrin-Eph pathway characterization and function. The Eph receptor tyrosine kinases and their membrane-tethered ephrin ligands provide critical guidance cues at points of cell-to-cell contact 140 . EphB receptors and their ephrin-B ligands are critical in the regulation of developmental angiogenesis and pericyte-endothelial cell interactions during vascular assembly, as shown in vivo by genetic loss-of-function studies 140 . Ephrin-B ligands and EphB receptors mark angiogenic vessels in vivo in the developing murine retina 141 . Studies in transgenic Pdgfrb-Cre;Efnb2 lox/lox mice reveal that ephrin-B2-EphB4 signaling controls pericyte directional migration and adhesion to maturing vessels 142 . Studies using genetically engineered mice in which the lacZ coding region substitutes and reports for the Efnb2 coding region have shown that ephrin-B2 is expressed in brain pericytes and endothelial cells 143 . Moreover, EphB4 controls blood vascular morphogenesis during postnatal angiogenesis 144 . Thus, ehprin-B2 and its receptor EphB4 can participate in vascular remodeling and in different aspects of NVU formation. The ephrin-B-EphB pathway is activated bidirectionally 143 : ephrin-B binding to EphB receptors causes phosphorylation of both the ephrin-B transmembrane ligand and its EphB receptor 141 .
Other pericyte-endothelial cell communication pathways. Signaling between integrin α 4 β 1 expressed by proliferating but not quiescent endothelial cells and vascular cell adhesion molecule-1 (VCAM-1) expressed by proliferating but not quiescent pericytes is critical for cell-cell adhesion events required for survival of endothelial and mural cells during vascularization, as shown both by in vitro and in vivo studies 145 . Blocking N-cadherin function leads to defective pericyte adhesion, increased pericyte recruitment and disturbed vascular morphogenesis, as shown in chicken embryos 146 . Studies using in vitro pluripotent embryonic stem cells demonstrate that N-cadherin is required for the maturation of endothelial sprouts by interacting with pericytes 147 . Endosialin is not expressed in the normal human adult brain 148, 149 or the adult mouse brain 150 , but is abundantly expressed in brain pericytes in the developing murine CNS 150 and tumor vessel-associated pericytes 149 , suggesting that its expression in sites of active tissue remodeling and neovascularization might have implications for angiogenesis, tumor growth and metastasis.
Pericyte-astrocyte signal transduction CypA-NFkB-MMP-9 pathway characterization and function. Astrocyte-secreted apolipoprotein E (APOE) interacts with cellsurface LRP1 on pericytes, which regulates activation of the proinflammatory BBB-degrading cyclophilin A (CypA)-NFκB-MMP-9 pathway in an isoform-specific manner (i.e., APOE4 but not APOE2 or APOE3 acts in this way) 11 (Fig. 5) . The increased MMP-9 activity triggered by APOE4, but not APOE2 and APOE3, in the vessel wall leads to degradation of endothelial tight junction and basement membrane proteins causing BBB breakdown 11 which in turn leads to brain accumulation of blood-derived neurotoxic molecules and erythrocytes and to secondary neurodegenerative changes.
CypA-NFkB-MMP-9 signaling in Alzheimer's disease. The cerebrovascular contributions to dementia and Alzheimer's disease are particularly salient in individuals carrying the APOE4 gene, the major genetic risk factor for late-onset sporadic Alzheimer's disease 83 . Increases in CypA and MMP-9 CSF levels were recently reported to correlate with BBB breakdown in human APOE4 carriers, but not in age-matched APOE2 or APOE3 carriers with intact BBBs 49 . Additionally, post-mortem analysis in APOE4-positive people with Alzheimer's disease compared to non-carriers reveals increased CypA and MMP-9 protein levels in hippocampal and cortical pericytes, as well as pericyte degeneration 50, 151 . Animal studies have demonstrated that BBB breakdown in APOE4 transgenic mice, but not in APOE3 or APOE2 transgenic mice 11, 152, 153 , results in neuronal injury and neurodegeneration 11 .
Arachidonic acid pathway. Astrocytes have been proposed to regulate pericyte tone via some of the same signaling pathways as reported for astrocyte-mediated regulation of VSMCs tone 6, 30 (Fig. 5) . The arachidonic acid pathway was shown to have a critical role in the regulation of pericyte tone and capillary diameter in studies using rat brain slices and retinal explants 35 . In vivo studies in the murine cortex have shown that arachidonic acid is metabolized in astrocytes to prostaglandin E 2 (PGE 2 ) by cyclooxtgenase-1, which has been shown to regulate hemodynamic responses 154 . Studies using rat cerebellar slices and retinal explants have shown that PGE 2 activates EP4 receptors in pericytes, leading to pericyte relaxation after addition of glutamate to slices 30 . Arachidonic acid secreted by astrocytes is metabolized to 20-hydroxyeicosatetraenoic acid (20-HETE) in pericytes by membrane-bound cytochrome P450 4A, as shown in rat cerebral arterial microsomes and brain slices 30, 155 . In turn, 20-HETE leads to contraction of pericytes in cerebral slices and retinal explants 30, 35 . Although the idea that the arachidonic acid pathway in astrocytes controls pericyte tone and capillary diameter is supported by studies in brain slices, in vivo evidence is still lacking.
Ca 2+
i -calmodulin-myosin light chain pathway. Intracellular Ca 2+ (Ca 2+ i ) increases in response to voltage-gated Ca 2+ channels, as shown in vitro in primary rat brain pericytes 156 and isolated rat retinal microvascular pericytes 157 , and in response to reactive oxygen species (ROS), as shown in vitro in human microvascular pericytes 158 , ex vivo in rat cerebellar slices 30 and in vivo in murine pericytes following ischemic stroke 46 . An increase in extracellular K + activates voltagegated Ca 2+ channels, resulting in Ca 2+ i increases and depolarization and contraction of primary rat brain pericytes 156 . Increased Ca 2+ i in pericytes is shown to promote contraction, possibly via downstream signaling through calmodulin and myosin light chain kinase to phosphorylate myosin light chain and induce contraction, by analogy to events described in VSMCs of isolated rat cerebral arteries 159 . npg r e v i e w Figure 5 Pericyte-astrocyte and pericyte-neuron signaling pathways. Astrocytes (top left, green) secrete APOE2 and APOE3 that bind to lipoprotein LRP1 receptor on pericytes (bottom, pink) to inhibit the downstream CypA-NFκB-MMP-9 pathway. In contrast, APOE4 binds weakly to LRP1, which activates the proinflammatory CypA-NFκB-MMP-9 cascade leading to BBB breakdown. Astrocyte Ca 2+ i increases in response to neuronal factors such as glutamate, which promotes phospholipase A 2 (PLA 2 )-mediated arachidonic acid (AA) generation. In astrocytes, AA is metabolized into PGE 2 via cyclooxygenase-1 (Cox1), as well as into epoxyeicosatrienoic acids (EET) via cytochrome (Cyt) P450. Astrocytic AA is metabolized into 20-HETE in mural cells via membrane-bound Cyt P450 4A, which promotes pericyte contraction. PGE 2 from astrocytes binds to the pericyte EP4 receptor, which alters K + conductance and promotes pericyte relaxation. In neurons (top right, blue), neuronal nitric oxide synthase (nNOS) generates NO, which inhibits Cyt P450 in astrocytes and Cyt P450 4A in pericytes to prevent AA to EET and AA to 20-HETE metabolism, respectively. In pericytes, increased cAMP signals via protein kinase A (PKA) to inhibit myosin light chain (MYL) phosphorylation and prevent pericyte contraction. Pericyte Ca 2+ i increases in response to voltage-gated Ca 2+ channels and ROS. Increased Ca 2+ i in pericytes promotes contraction, possibly via downstream signaling through calmodulin (CaM) and myosin light chain kinase (MLCK) which phosphorylates MYL to induce contraction, as shown in VSMCs. Conversely, decreasing Ca 2+ i in pericytes inhibits Ca 2+ -gated chloride channels which promotes relaxation. Furthermore, neurotransmitters promote pericyte relaxation (for example, glutamate, dopamine, adenosine) or contraction (for example, norepinephrine). Specifically, adenosine signals through adenosine A1 and A2 receptors (A1R, A2R) on pericytes to alter K + conductance and promote pericyte relaxation. Red lines, inhibitory mechanisms; black lines, activating mechanisms.
Pericytes were recently shown to express Myl9, which encodes myosin light chain regulatory polypeptide 9, in single-cell RNA-seq analysis of the murine cortex 160 . Treating isolated rat retinal microvascular pericytes with a cyclic guanosine monophosphate analog inhibits voltage-gated Ca 2+ channels, decreases Ca 2+ i and inhibits Ca 2+ -gated chloride channels, which decreases whole-cell Ca 2+ and Cl -currents and promotes pericyte relaxation 157 .
Pericyte-neuron interactions
Neuronal innervation of pericytes covering brain capillaries is not as well understood as neuronal innervation of VSMCs surrounding arterioles and small arteries 161 although capillaries are more numerous and more densely spaced than arterioles, as shown, for example, in the mouse cortex 162 . Moreover, the average distance between a neuron and a capillary is 8-23 µm in the mouse hippocampus, while the average distance between a neuron and an arteriole is 70-160 µm (ref. 163) , suggesting that pericytes and capillaries are well positioned to receive chemical transmitters from activated neurons and are likely to respond earlier to changes in neuronal activity than VSMCs.
Neurotrophic factors. Cultured human brain pericytes express levels of neurotrophic factors that are low but comparable to the amounts produced by cultured astrocytes 164 . The functional importance of these findings remains unknown. A recent study using a murine hypothalamic GT1-7 cell line has shown that only pericyte-derived media, but not astrocyte or VSMC media, increase the insulin-stimulated phosphorylation of Akt in GT1-7 cells and insulin-dependent tyrosine phosphorylation of insulin receptor β (ref. 165) , suggesting that pericytes rather than astrocytes and VSMCs can increase insulin sensitivity in hypothalamic neurons by releasing soluble factors. Given the strategic location of pericytes within the NVU, it is possible that pericyte-derived molecules may be distributed in the NVU and reach their neuronal targets by para-arterial CSF-interstitial fluid flow 166 or perivascular flow 167 .
Neurotransmitters. Studies using bovine retinal pericytes 168 and ex vivo rat cerebellar slices and retinal explants 30, 35 show that norepinephrine leads to pericyte contraction and reduction of capillary diameter. Neurotransmitters that lead to pericyte relaxation include GABA, as shown ex vivo in rat cerebellar slices 35 ; adenosine, as shown in vitro in rat retinal pericytes 169 ; glutamate, as shown ex vivo in rat cerebellar slices 30 ; and dopamine, as shown ex vivo in rat retinal pericytes 170 . Studies in rat cerebellar slices and retinal explants also show that glutamate suppresses pericyte contractility through PGE 2 30,35 and that nitric oxide blocks 20-HETE-induced pericyte contraction by inhibiting arachidonic acid conversion to 20-HETE, resulting in capillary dilation 30 (Fig. 5) . Recent in vivo studies have provided important evidence for neuronal control of capillary circulation by showing that capillaries dilate ahead of arterioles in the mouse cortex in response to whisker stimulation 30 .
Integrating pathways: toward a systems biology approach Recent studies have also focused on modeling the BBB, NVU and pericyte functions in blood vessels [171] [172] [173] . A computational model predicting disruption of blood vessel development incorporates endothelial, inflammatory and mural cells (i.e., pericytes) 172 . A physical threedimensional, multi-compartment, organotypic microphysiological system representative of the NVU-an NVU on a chip-recapitulates all critical barriers in the brain, including BBB, brain-CSF barrier and blood-CSF barrier 171 . It has been suggested that in silico modeling might even more rapidly enhance our understanding of the NVU than in vitro cell-based modeling 173 , but it requires a critical level of biological understanding to successfully bridge the logical connectivity of molecular pathways with computational integration systems 174 . npg r e v i e w Figure 6 Integrated pathways between pericytes, endothelial cells and astrocytes in the NVU. A proposed three-layered model of the NVU. The first layer, NVU cells, is the foundational layer of cell-type-specific systems, each of which consists of integrated modular molecular pathways. We show the endothelial cell (yellow) partitioned into 12 pathways ( Supplementary  Fig. 1 ), the pericyte (pink) partitioned into 13 pathways (Supplementary Fig. 2 ) and the astrocyte (green) partitioned into 2 pathways (Supplementary Fig. 3 ). Each major signal transduction pathway within each NVU cell type also provides for the modular addition of new signaling pathways. The second layer, interactive signaling, instantiates the converging points of interactions of key signaling pathways between pericytes-endothelial cells and pericytesastrocytes. The pericyte-endothelial signaling (coral box) in the second layer consists of 6 major signaling pathways: MFSD2A, Notch, TGF-β-TGFβR2, VEGF-A-VEGFR2, Ang-Tie2 and PDGF-BB-PDGFRβ. The pericyte-astrocyte signaling (purple box), also at the second layer, consists of 3 major signaling pathway: CypA-NFκB-MMP-9, arachidonic acid and Ca 2+ i -calmodulin-myosin light chain (MYL). The third layer, disorders, proposes major signaling pathways of CNS pericytes with neighboring NVU cell types (i.e., endothelial cells and astrocytes) that are suggested to contribute to pericyte dysfunction in neurological disorders, including microcephaly, CCM, IVH, hypoxia, ischemic stroke, cancer, type 2 diabetes mellitus (T2DM), ALS, HIV-associated dementia (HAD) and HIV-associated neurocognitive disorders (HAND), Fahr's disease, Alzheimer's disease (AD) and megalencephalic leukoencephalopathy with subcortical cysts (MLC).
Here we schematically illustrate a multilayered model of the NVU with (i) an interconnected system of pathways in endothelial cells, pericytes and astrocytes (NVU cell layer); (ii) converging points of key signaling pathways in CNS pericytes, between pericytes and endothelial cells, and between pericytes and astrocytes (interactive signaling layer); and (iii) the potential impact of such convergent pathways to neurological disorders (disorders layer) (Fig. 6) . Since all these processes may be species, strain, disease or context dependent, we provide Figure 6 as an all-inclusive data source and encourage the readers to explore and critically examine the specifics in the existing literature.
Future directions
Several functions of pericytes, such as capillary contractility, neuroinflammation and multipotent stem cell activity, are still to be fully characterized. It is also unclear how each pericyte subtype contributes to pericyte function, such as, for example, control of CBF versus control of BBB integrity. Developing genetic models with mural cell-specific ablation along the vascular tree combined with RNA-seq and proteomic analyses would greatly facilitate the study of CNS pericytes and other mural cell subpopulations.
Many studies have pointed toward pericytes as an attractive cellular target in rare genetic neurological disorders such as Fahr's disease, IVH, CCM and CADASIL. A growing body of evidence also indicates that targeting pericytes could be an important treatment option for controlling growth of brain tumors including glioblastoma, as well as improving vascular remodeling and stabilization of the BBB in Alzheimer's disease and possibly other neurodegenerative diseases. The potential of targeting pericytes to open the BBB on demand and/ or to stabilize dysregulated CBF is another important area for future studies because of pericytes' emerging role in brain diseases affecting BBB and CBF, such as stroke and Alzheimer's disease.
The systems biology approach can help address some emerging questions in the field, such as, for example, whether some of the pathways identified in rare monogenic neurological diseases caused by genetic defects in pericytes, endothelial cells or astrocytes that lead to NVU disruption converge with complex neurological disorders, such as sporadic Alzheimer's disease, ALS and others, associated with pericyte and BBB dysfunction. Computational modeling of CNS pericytes combined with high-throughput screening of diverse libraries of compounds is also likely to advance discovery of therapeutics for neurological disorders based on correcting aberrant signaling and function of pericytes and their neighboring cell types in the NVU. 
